NICE recommends gene therapy for severe sickle cell disease
By Catherine Eckford (European Pharmaceutical Review)
UK enhances ILAP to accelerate access to innovative medicines
By European Pharmaceutical Review
Biosimilar medicines: the intersection of access, affordability, and innovation
By Julie Maréchal-Jamil (Medicines for Europe)
Takeda plans 2026 CEO succession
By Catherine Eckford (European Pharmaceutical Review)
Harnessing industry advancements to accelerate upstream process development
By Dr Li Yang (Altruist Biologics), Dr Shidong Shi (Altruist…
Considerations for a successful tech transfer of a biologics upstream…
By Maolong Liu (Lonza Biologics), Neil Judd (Lonza), Nikki Nogal…